Karyopharm Therapeut (KPTI): Congress and insider trades
Who in Congress and inside the company traded KPTI, when each filing appeared, and what buying after each one would have earned against the S&P 500.
Key Facts
- Karyopharm Therapeut (KPTI) is a listed stock on NASDAQ.
- Insiders filed 0 open market buys worth $0 and 3 sells worth $5.4K, the latest filed 2026-09-02 (2 September 2026).
- Data as of 2026-09-29 (29 September 2026).
Insider trades in KPTI
as of 2026-09-02| Filed | Insider | Type | Shares | Price | Value | 90 day vs S&P |
|---|---|---|---|---|---|---|
| 2 Sep 2026 | Abate Kristin | sell | 19 | $2.02 | $38 | n/a |
| 30 Jul 2026 | Poulton Stuart | sell | 189 | $7.10 | $1.3K | n/a |
| 22 Apr 2026 | Rangwala Reshma | sell | 449 | $8.94 | $4.0K | n/a |
Nothing matches that search.
Related pages
Frequently asked questions
Who has bought KPTI?
0 Congress buys by 0 members and 0 insider buys are on file. The tables on this page list every one.
Did buying KPTI after a disclosure beat the market?
No disclosed buy of this stock has matured 90 days yet. A single stock is a small sample.
Sources: Congressional trades: STOCK Act disclosures, collected from CapitolTrades. Insider trades: SEC Form 4 filings, collected from Finviz. Prices: Yahoo Finance daily adjusted closes. Data as of 2026-09-29 (29 September 2026). About these sources.
Not investment advice. Past disclosed trades do not predict future returns. Disclosures are published late, so the trades shown are ones you could only have copied after the fact. Talk to a licensed adviser before you invest.